These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15521370)

  • 41. Intranasal steroid sprays in the treatment of rhinitis: is one better than another?
    Waddell AN; Patel SK; Toma AG; Maw AR
    J Laryngol Otol; 2003 Nov; 117(11):843-5. PubMed ID: 14670141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New therapeutic options for allergic rhinitis: back to the future with intranasal corticosteroid aerosols.
    Carr WW
    Am J Rhinol Allergy; 2013; 27(4):309-13. PubMed ID: 23816748
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis.
    Anolik R;
    Ann Allergy Asthma Immunol; 2008 Mar; 100(3):264-71. PubMed ID: 18426147
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.
    Ratner PH; Hampel F; Van Bavel J; Amar NJ; Daftary P; Wheeler W; Sacks H
    Ann Allergy Asthma Immunol; 2008 Jan; 100(1):74-81. PubMed ID: 18254486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Respiratory procedures. Part 6--Use of nasal sprays in allergic rhinitis.
    Burns D
    Nurs Times; 2007 Sep 11-17; 103(37):24-5. PubMed ID: 17902591
    [No Abstract]   [Full Text] [Related]  

  • 46. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis.
    Jen A; Baroody F; de Tineo M; Haney L; Blair C; Naclerio R
    J Allergy Clin Immunol; 2000 Apr; 105(4):732-8. PubMed ID: 10756223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [How to use intranasal corticosteroid in patients with allergic rhinitis: knack and pitfall].
    Masuyama K
    Arerugi; 2009 Jun; 58(6):620-9. PubMed ID: 19571654
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.
    Berger W; Abelson MB; Gomes PJ; Beck M; Kimura S; Westbrook T; Storms W; Galant S
    Ann Allergy Asthma Immunol; 2005 Oct; 95(4):361-71. PubMed ID: 16279567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current categorisation of allergic rhinitis and sensory perceptions to intranasal corticosteroids: clinical implications.
    Shah A
    Indian J Chest Dis Allied Sci; 2005; 47(3):157-9. PubMed ID: 16022141
    [No Abstract]   [Full Text] [Related]  

  • 50. Ciclesonide, a hypotonic intranasal corticosteroid.
    Neffen H; Wingertzahn MA
    Allergy Asthma Proc; 2010; 31 Suppl 1():S29-37. PubMed ID: 20557684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of intranasal corticosteroids.
    Grzincich G; Capra L; Cammarata MG; Spaggiari C; Pisi G
    Acta Biomed; 2004 Apr; 75(1):22-5. PubMed ID: 15315083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intranasal Steroid Use and Satisfaction in Allergic Rhinitis: A Cross-Sectional Study from an Asian Perspective.
    Lee BW; Lee CS; Lim ER; Tham AC
    ORL J Otorhinolaryngol Relat Spec; 2022; 84(1):55-61. PubMed ID: 34167110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis?
    Keith PK; Scadding GK
    Curr Med Res Opin; 2009 Aug; 25(8):2021-41. PubMed ID: 19569975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey.
    Maurer M; Zuberbier T
    Allergy; 2007 Sep; 62(9):1057-63. PubMed ID: 17581263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Link between patient preferences and treatment outcomes in seasonal allergic rhinitis: an empiric investigation.
    Ricard N; Kind P; Christian S; Jensen M; Stewart J
    Clin Ther; 1999 Jan; 21(1):268-77. PubMed ID: 10090440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Suggested updated approaches to patient management.
    Katial RK; Meltzer EO; Lieberman P; Ratner PH; Berger WE; Kaliner MA; Siegel CJ; Bukstein DA; Ciervo CA; Marple B
    Ann Allergy Asthma Immunol; 2011 Feb; 106(2 Suppl):S17-9. PubMed ID: 21277529
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis.
    Blaiss MS
    Allergy Asthma Proc; 2007; 28(2):145-52. PubMed ID: 17479597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: a white paper.
    Luskin AT; Blaiss MS; Farrar JR; Settipane R; Hayden ML; Stoloff S; Chadwick SJ; Derebery MJ; Ettari MP; Luskin S; Naclerio R
    Allergy Asthma Proc; 2011; 32(2):168-77. PubMed ID: 21352638
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expanding choices in intranasal steroid therapy: summary of a roundtable meeting.
    Blaiss MS; Benninger MS; Fromer L; Gross G; Mabry R; Mahr T; Marple B; Stoloff S
    Allergy Asthma Proc; 2006; 27(3):254-64. PubMed ID: 16913270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids.
    Hankin CS; Cox L; Lang D; Bronstone A; Wang Z; Lepore MS; Buck PO
    Allergy Asthma Proc; 2012; 33(3):258-64. PubMed ID: 22737709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.